Skip to main content

Advertisement

Table 3 Comparison between SLE patients with and without atherosclerotic plaques

From: Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus

  SLE patients
  With plaque (n= 49) Without plaque (n= 62) P
Age, years 55.79 ± 9.23 41.7 ± 12.76 < 0.001
Disease duration, mean 14.00 years 9.82 years 0.025
Current smokers, % (no.) 7.2% (n = 8) 6.3% (n = 7) 0.44
Presence of hypertension,% (no.) 31.5% (n = 35) 27% (n = 30) 0.014
Presence of diabetes,% (no.) 4.5% (n = 5) 0.9% (n = 1) 0.047
HOMA IR 1.41 (0.91 to 1.94) 1.20 (0.73 to 1.94) 0.41
Glucos (mmol/L) 4.70 (4.30 to 5.00) 4.35 (3.90 to 4.70) 0.0013
LDL(mmol/L) 2.87 ± 1.05 2.28 ± 0.66 0.001
Hyperlipidemia (LDL > 3) 38.77 (n = 19) 19.35 (n = 12) 0.023
Kolesterol (mmol/L) 5.05 ± 1.26 4.35 ± 0.98 0.001
ApoB/ApoA1, median 0.60 (0.50 to 0.80) 0.50 (0.45 to 0.60) 0.004
High sensitivity CRP, mg/l 1.85 (0.82 to 4.05) 1.75 (0.69 to 4.8) 0.980
Triglicerides (mmol/L) 1.00 (0.74 to 1.50) 0.94 (0.61 to 1.30) 0.065
BMI (kg/m2) 25.95 (22.28 to 28.41) 24.16 (20.08 to 26.84) 0.032
SLAM 6.00 (5 to 9) 6.50 (4 to 10) 0.41
SLEDAI 2 (0 to 5) 2 (0 to 6) 0.46
SLICC 1 (0 to 4) 1(0 to 2) 0.39
Lupus anticoagulans 10.81% (n = 12) 14.41% (n = 16) 0.87
Anticardiolipin Ab 8.18% (n = 9) 11.81% (n = 13) 0.70
Beta 2 glycoprotein 1 15.45% (n = 17) 18.18% (n = 20) 0.83
Cumulative lifetime glukocorticoid dose/year (g/year) 2.49 (1.75 to 3.68) 2.59 (1.87 to 3.49) 0.952
Glucocorticoid last year, gram 0.9 (0 to 2.19) 1.8 (0.07 to 2.70) 0.093
Chloroquin/hydroxychlorochine 42.85% (n = 21) 54.83% (n = 34) P = 0.210
IgM antiPC 48.75 (25.79 to 104.78) 85.94 (50.02 to 231.52) P = 0.001
IgM antiPC < = 10th percentile (%) 23.40 10.17 0.0651
IgM antiPC < = 25th percentile (%) 40.43 23.73 0.0651
IgM antiPC < = 33th percentile (%) 57.45 28.81 0.0030
  1. anti-PC, antibodies against PC; CR, C-reactive protein; HDL, high density lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL, low density lipoprotein; PC, phosphorylcholine; SLAM, Systemic Lupus Activity Measure; SLEDAI, Systemic Lupus Erythematosus diseases activity index; SLICC, Systemic Lupus International Collaborating Clinics damage index.